Renata Curi Hauegen

Risk sharing agreements: acordos de partilha de risco e o sistema público de saúde no Brasil - oportunidades e desafios

Renata Curi Hauegen, 2014 .

Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab

Steven Simoens, Brian Godman, Renata Curi Hauegen, 2019, Applied Health Economics and Health Policy.

Time to review authorisation and funding for new cancer medicines in Europe? Inferences from the case study with olaratumab.

Renata Curi Hauegen, S. Simoens, C. Nadal, 2019 .

Integrative Review of Managed Entry Agreements: Chances and Limitations

André Luiz Pereira, Renata Curi Hauegen, S. Simoens, 2020, PharmacoEconomics.

Public participation in decision-making on the coverage of new antivirals for hepatitis C.

Renata Curi Hauegen, J. Whitty, K. Chalkidou, 2016, Journal of health organization and management.

[The incorporation of nusinersen by the Brazilian Unified National Health System: critical thoughts on the institutionalization of health technology assessment in Brazil].

Renata Curi Hauegen, C. Osorio-de-Castro, R. Caetano, 2019, Cadernos de saude publica.

Patterns of public participation.

Renata Curi Hauegen, J. Whitty, S. Staniszewska, 2016, Journal of health organization and management.

Biodiversity and the patent system: the Brazilian case

Renata Curi Hauegen, F. Pimenta, P. B. Zorzal, 2020 .

Public participation in decision-making on the coverage of new antivirals for hepatitis C.

Renata Curi Hauegen, J. Whitty, K. Chalkidou, 2016, Journal of health organization and management.